US equities
|
META
$642.62
▲+0.00%
MU
$877.55
▲+0.00%
TSLA
$372.22
▲+0.00%
SPCX
$147.49
▲+0.00%
NVDA
$210.96
▲+0.00%
NU
$15.16
▲+0.00%
SNDK
$1,238.03
▲+0.00%
NBIS
$158.74
▲+0.00%
META
$642.62
▲+0.00%
MU
$877.55
▲+0.00%
TSLA
$372.22
▲+0.00%
SPCX
$147.49
▲+0.00%
NVDA
$210.96
▲+0.00%
NU
$15.16
▲+0.00%
SNDK
$1,238.03
▲+0.00%
NBIS
$158.74
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Samsung Bioepis Co., Ltd.
Samsung Bioepis Releases Fourth Quarter 2026 Biosimilar Market Report Highlighting Importance of Supply Continuity
October 22, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
October 01, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Releases Third Quarter 2026 Biosimilar Market Report
July 23, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
July 01, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)
June 29, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Releases Second Quarter 2026 US Biosimilar Market Report
April 27, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026
April 20, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate
April 14, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates
March 18, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Releases First Quarter 2026 US Biosimilar Market Report, Providing Updates to Evolving Drug Pricing Models
January 23, 2026
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Releases Fourth Quarter 2025 US Biosimilar Market Report Providing Annual Biosimilar Trends and Future Market Trajectory
October 23, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Releases Third Quarter 2025 US Biosimilar Market Report Exploring the Most-Favored-Nation (MFN) Policy and its Impact on Biosimilars
July 21, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
July 17, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis’ Second Quarter 2025 Biosimilar Market Report Highlights US Debut of Ustekinumab Biosimilars with WAC discounts over 80% and Regulatory Streamlining
April 24, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
February 24, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
FDA Approves Samsung Bioepis’ OSPOMYV™, XBRYK™ (denosumab-dssb), a Biosimilar to Prolia and Xgeva
February 15, 2025
From
Samsung Bioepis Co., Ltd.
Via
Business Wire
